Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM376WT)

Drug Name

NKTR 214 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Melanoma	2C30	Phase 3	[1]
Sarcoma	2A60-2C35	Phase 2	[2]
Bladder cancer	2C94	Phase 1/2	[3]
Colorectal cancer	2B91.Z	Phase 1/2	[3]
Renal cell carcinoma	2C90	Phase 1/2	[3]
Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[2]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Interleukin 2 receptor beta (IL2RB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
NKTR-214	DMACYW6	Melanoma	2C30	Phase 3	[4]
AFTVac	DMD3XMG	Glioblastoma multiforme	2A00.0	Phase 2	[5]
Leukocyte interleukin	DM2B0TJ	Head and neck cancer	2D42	Phase 1	[6]
DAB-486-IL-2	DM54T8J	Discovery agent	N.A.	Investigative	[7]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Interleukin 2 receptor beta (IL2RB)	TT9721Y	IL2RB_HUMAN	Agonist	[3]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT03635983) A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy. Nat Commun. 2020 Jan 31;11(1):661.
5	Phase II randomized trial of autologous formalin-fixed tumor vaccine for postsurgical recurrence of hepatocellular carcinoma. Clin Cancer Res. 2004 Mar 1;10(5):1574-9.
6	Leukocyte Interleukin, Inj. (LI) augmentation of natural killer cells and cytolytic T-lymphocytes. Immunopharmacol Immunotoxicol. 1995 May;17(2):247-64.
7	Interleukin 2 receptor targeted fusion toxin (DAB486-IL-2) treatment blocks diabetogenic autoimmunity in non-obese diabetic mice. Eur J Immunol. 1992 Mar;22(3):697-702.